Clinical Experience With Radiation Therapy in the Management of Neurofibromatosis-Associated Central Nervous System Tumors

Stacy Wentworth, Melva Pinn, J. Daniel Bourland, Allan F. deGuzman, Kenneth Ekstrand, Thomas L. Ellis, Steven S. Glazier, Kevin P. McMullen, Michael Munley, Volker W. Stieber, Stephen B. Tatter, Edward G. Shaw

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Purpose: Patients with neurofibromatosis (NF) develop tumors of the central nervous system (CNS). Radiation therapy (RT) is used to treat these lesions. To better define the efficacy of RT in these patients, we reviewed our 20-year experience. Methods and Materials: Eighteen patients with NF with CNS tumors were treated from 1986 to 2007. Median follow-up was 48 months. Progression was defined as growth or recurrence of an irradiated tumor on serial imaging. Progression-free survival (PFS) was measured from the date of RT completion to the date of last follow-up imaging study. Actuarial rates of overall survival (OS) and PFS were calculated according to the Kaplan-Meier method. Results: Eighty-two tumors in 18 patients were irradiated, with an average of five tumors/patient. Median age at treatment was 25 years (range, 4.3-64 years). Tumor types included acoustic neuroma (16%), ependymoma (6%), low-grade glioma (11%), meningioma (60%), and schwanomma/neurofibroma (7%). The most common indication for treatment was growth on serial imaging. Most patients (67%) received stereotactic radiosurgery (median dose, 1,200 cGy; range, 1,000-2,400 cGy). The OS rate at 5 years was 94%. Five-year PFS rates were 75% (acoustic neuroma), 100% (ependymoma), 75% (low-grade glioma), 86% (meningioma), and 100% (schwanomma/neurofibroma). Thirteen acoustic neuromas had a local control rate of 94% with a 50% hearing preservation rate. Conclusions: RT provided local control, OS, and PFS rates similar to or better than published data for tumors in non-NF patients. Radiation therapy should be considered in NF patients with imaging progression of CNS tumors.

Original languageEnglish (US)
Pages (from-to)208-213
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume73
Issue number1
DOIs
StatePublished - Jan 1 2009
Externally publishedYes

Fingerprint

Central Nervous System Neoplasms
central nervous system
Neurofibromatoses
radiation therapy
Radiotherapy
tumors
progressions
Disease-Free Survival
Acoustic Neuroma
Survival Rate
Ependymoma
Neurofibroma
Meningioma
Neoplasms
Glioma
acoustics
grade
Radiosurgery
hearing
Growth

Keywords

  • Acoustic neuroma
  • Meningioma
  • Neurofibromatosis
  • Radiation therapy
  • Radiosurgery

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Clinical Experience With Radiation Therapy in the Management of Neurofibromatosis-Associated Central Nervous System Tumors. / Wentworth, Stacy; Pinn, Melva; Bourland, J. Daniel; deGuzman, Allan F.; Ekstrand, Kenneth; Ellis, Thomas L.; Glazier, Steven S.; McMullen, Kevin P.; Munley, Michael; Stieber, Volker W.; Tatter, Stephen B.; Shaw, Edward G.

In: International Journal of Radiation Oncology Biology Physics, Vol. 73, No. 1, 01.01.2009, p. 208-213.

Research output: Contribution to journalArticle

Wentworth, S, Pinn, M, Bourland, JD, deGuzman, AF, Ekstrand, K, Ellis, TL, Glazier, SS, McMullen, KP, Munley, M, Stieber, VW, Tatter, SB & Shaw, EG 2009, 'Clinical Experience With Radiation Therapy in the Management of Neurofibromatosis-Associated Central Nervous System Tumors', International Journal of Radiation Oncology Biology Physics, vol. 73, no. 1, pp. 208-213. https://doi.org/10.1016/j.ijrobp.2008.03.073
Wentworth, Stacy ; Pinn, Melva ; Bourland, J. Daniel ; deGuzman, Allan F. ; Ekstrand, Kenneth ; Ellis, Thomas L. ; Glazier, Steven S. ; McMullen, Kevin P. ; Munley, Michael ; Stieber, Volker W. ; Tatter, Stephen B. ; Shaw, Edward G. / Clinical Experience With Radiation Therapy in the Management of Neurofibromatosis-Associated Central Nervous System Tumors. In: International Journal of Radiation Oncology Biology Physics. 2009 ; Vol. 73, No. 1. pp. 208-213.
@article{41148a954aa1427999e9a5da865ba9ac,
title = "Clinical Experience With Radiation Therapy in the Management of Neurofibromatosis-Associated Central Nervous System Tumors",
abstract = "Purpose: Patients with neurofibromatosis (NF) develop tumors of the central nervous system (CNS). Radiation therapy (RT) is used to treat these lesions. To better define the efficacy of RT in these patients, we reviewed our 20-year experience. Methods and Materials: Eighteen patients with NF with CNS tumors were treated from 1986 to 2007. Median follow-up was 48 months. Progression was defined as growth or recurrence of an irradiated tumor on serial imaging. Progression-free survival (PFS) was measured from the date of RT completion to the date of last follow-up imaging study. Actuarial rates of overall survival (OS) and PFS were calculated according to the Kaplan-Meier method. Results: Eighty-two tumors in 18 patients were irradiated, with an average of five tumors/patient. Median age at treatment was 25 years (range, 4.3-64 years). Tumor types included acoustic neuroma (16{\%}), ependymoma (6{\%}), low-grade glioma (11{\%}), meningioma (60{\%}), and schwanomma/neurofibroma (7{\%}). The most common indication for treatment was growth on serial imaging. Most patients (67{\%}) received stereotactic radiosurgery (median dose, 1,200 cGy; range, 1,000-2,400 cGy). The OS rate at 5 years was 94{\%}. Five-year PFS rates were 75{\%} (acoustic neuroma), 100{\%} (ependymoma), 75{\%} (low-grade glioma), 86{\%} (meningioma), and 100{\%} (schwanomma/neurofibroma). Thirteen acoustic neuromas had a local control rate of 94{\%} with a 50{\%} hearing preservation rate. Conclusions: RT provided local control, OS, and PFS rates similar to or better than published data for tumors in non-NF patients. Radiation therapy should be considered in NF patients with imaging progression of CNS tumors.",
keywords = "Acoustic neuroma, Meningioma, Neurofibromatosis, Radiation therapy, Radiosurgery",
author = "Stacy Wentworth and Melva Pinn and Bourland, {J. Daniel} and deGuzman, {Allan F.} and Kenneth Ekstrand and Ellis, {Thomas L.} and Glazier, {Steven S.} and McMullen, {Kevin P.} and Michael Munley and Stieber, {Volker W.} and Tatter, {Stephen B.} and Shaw, {Edward G.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1016/j.ijrobp.2008.03.073",
language = "English (US)",
volume = "73",
pages = "208--213",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Clinical Experience With Radiation Therapy in the Management of Neurofibromatosis-Associated Central Nervous System Tumors

AU - Wentworth, Stacy

AU - Pinn, Melva

AU - Bourland, J. Daniel

AU - deGuzman, Allan F.

AU - Ekstrand, Kenneth

AU - Ellis, Thomas L.

AU - Glazier, Steven S.

AU - McMullen, Kevin P.

AU - Munley, Michael

AU - Stieber, Volker W.

AU - Tatter, Stephen B.

AU - Shaw, Edward G.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Purpose: Patients with neurofibromatosis (NF) develop tumors of the central nervous system (CNS). Radiation therapy (RT) is used to treat these lesions. To better define the efficacy of RT in these patients, we reviewed our 20-year experience. Methods and Materials: Eighteen patients with NF with CNS tumors were treated from 1986 to 2007. Median follow-up was 48 months. Progression was defined as growth or recurrence of an irradiated tumor on serial imaging. Progression-free survival (PFS) was measured from the date of RT completion to the date of last follow-up imaging study. Actuarial rates of overall survival (OS) and PFS were calculated according to the Kaplan-Meier method. Results: Eighty-two tumors in 18 patients were irradiated, with an average of five tumors/patient. Median age at treatment was 25 years (range, 4.3-64 years). Tumor types included acoustic neuroma (16%), ependymoma (6%), low-grade glioma (11%), meningioma (60%), and schwanomma/neurofibroma (7%). The most common indication for treatment was growth on serial imaging. Most patients (67%) received stereotactic radiosurgery (median dose, 1,200 cGy; range, 1,000-2,400 cGy). The OS rate at 5 years was 94%. Five-year PFS rates were 75% (acoustic neuroma), 100% (ependymoma), 75% (low-grade glioma), 86% (meningioma), and 100% (schwanomma/neurofibroma). Thirteen acoustic neuromas had a local control rate of 94% with a 50% hearing preservation rate. Conclusions: RT provided local control, OS, and PFS rates similar to or better than published data for tumors in non-NF patients. Radiation therapy should be considered in NF patients with imaging progression of CNS tumors.

AB - Purpose: Patients with neurofibromatosis (NF) develop tumors of the central nervous system (CNS). Radiation therapy (RT) is used to treat these lesions. To better define the efficacy of RT in these patients, we reviewed our 20-year experience. Methods and Materials: Eighteen patients with NF with CNS tumors were treated from 1986 to 2007. Median follow-up was 48 months. Progression was defined as growth or recurrence of an irradiated tumor on serial imaging. Progression-free survival (PFS) was measured from the date of RT completion to the date of last follow-up imaging study. Actuarial rates of overall survival (OS) and PFS were calculated according to the Kaplan-Meier method. Results: Eighty-two tumors in 18 patients were irradiated, with an average of five tumors/patient. Median age at treatment was 25 years (range, 4.3-64 years). Tumor types included acoustic neuroma (16%), ependymoma (6%), low-grade glioma (11%), meningioma (60%), and schwanomma/neurofibroma (7%). The most common indication for treatment was growth on serial imaging. Most patients (67%) received stereotactic radiosurgery (median dose, 1,200 cGy; range, 1,000-2,400 cGy). The OS rate at 5 years was 94%. Five-year PFS rates were 75% (acoustic neuroma), 100% (ependymoma), 75% (low-grade glioma), 86% (meningioma), and 100% (schwanomma/neurofibroma). Thirteen acoustic neuromas had a local control rate of 94% with a 50% hearing preservation rate. Conclusions: RT provided local control, OS, and PFS rates similar to or better than published data for tumors in non-NF patients. Radiation therapy should be considered in NF patients with imaging progression of CNS tumors.

KW - Acoustic neuroma

KW - Meningioma

KW - Neurofibromatosis

KW - Radiation therapy

KW - Radiosurgery

UR - http://www.scopus.com/inward/record.url?scp=57649087701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57649087701&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2008.03.073

DO - 10.1016/j.ijrobp.2008.03.073

M3 - Article

C2 - 18687535

AN - SCOPUS:57649087701

VL - 73

SP - 208

EP - 213

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 1

ER -